Bensaid M, Gary-bobo M, Esclangon A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908-914 (2003).
Cabral GA, Griffin-Thomas L. Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects. Expert reviews in molecular medicine 2009;11:e3. doi:10.1017/S1462399409000957.
Choukèr, Alexander, et al. “Motion sickness, stress and the endocannabinoid system.” PLoS One 5.5 (2010): e10752.
D’Argenio, Giuseppe, et al. “Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.” The FASEB journal 20.3 (2006): 568-570.
Devane, William A., et al. “Determination and characterization of a cannabinoid receptor in rat brain.” Molecular pharmacology 34.5 (1988): 605-613.
Devane, William A., et al. “Isolation and structure of a brain constituent that binds to the cannabinoid receptor.” Science 258.5090 (1992): 1946-1949.
Di FM, Pini LA, Pelliccioli GP, Calabresi P, Sarchielli P (2008) Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol Neurosurg Psychiatry 79: 1224–1229
Di Marzo, Vincenzo, and Isabel Matias. “Endocannabinoid control of food intake and energy balance.” Nature neuroscience 8.5 (2005): 585-589.
Di Marzo, V., et al. “Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors.” Diabetologia 52.2 (2009): 213-217.
Di Marzo, V. “The endocannabinoid system in obesity and type 2 diabetes.” Diabetologia 51.8 (2008): 1356-1367.
Di Marzo, V., et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neuroscience (1998) 21: 521–528.
Duncan, M., J. S. Davison, and K. A. Sharkey. “Review article: endocannabinoids and their receptors in the enteric nervous system.” Alimentary pharmacology & therapeutics 22.8 (2005): 667-683.
Dunnett, Alenka J., et al. “The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase.” Journal of Bodywork and Movement Therapies 11.2 (2007): 99-105.
Ferguson, G., and M. A. Ware. “Review Article: Sleep, Pain and Cannabis.” Journal of Sleep Disorders & Therapy 2015 (2015).
Fride, Ester, Tatyana Bregman, and Tim C. Kirkham. “Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood.” Experimental Biology and Medicine 230.4 (2005): 225-234.
Gaoni, Yechiel, and Raphael Mechoulam. “Isolation, structure, and partial synthesis of an active constituent of hashish.” Journal of the American Chemical Society 86.8 (1964): 1646-1647.
Hajrasouliha, Amir Reza, et al. “Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB 2 receptors in the rat heart.” European journal of pharmacology 579.1 (2008): 246-252.
Herkenham, M., et al, Cannabinoid Receptor Localization in Brain. Proceedings of the National Academy of Sciences USA 87 (1990): 1932-36
Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34: 1257–1268
Hill, M. N., and B. B. Gorzalka. “Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?.” Behavioural pharmacology 16.5-6 (2005): 333-352.
Hirvonen, J., et al. “Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.” Molecular psychiatry 17.6 (2012): 642-649.
Hungund, B. L., et al. “Upregulation of CB1 receptors and agonist-stimulated (35S)GTPγS binding in the prefrontal cortex of depressed suicide victims.” Molecular psychiatry 9.2 (2004): 184-190.
Kathuria, Satish, et al. “Modulation of anxiety through blockade of anandamide hydrolysis.” Nature medicine 9.1 (2003): 76-81.
Kaufmann, I., et al. “Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report.” European Surgical Research 43.4 (2009): 325-329.
Koethe, Dagmar, et al. “Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.” The British Journal of Psychiatry 194.4 (2009): 371-372.
Ludányi, Anikó, et al. “Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.” The Journal of neuroscience 28.12 (2008): 2976-2990.
Maccarrone, M. “CB2 receptors in reproduction.” British journal of pharmacology 153.2 (2008): 189-198.
Manzanares, J., et al. "Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes." Current neuropharmacology 4.3 (2006): 239-257.
Matias, Isabel, et al. “Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia.” The Journal of Clinical Endocrinology & Metabolism 91.8 (2006): 3171-3180.
Mechoulam, Raphael, et al. “Early phytocannabinoid chemistry to endocannabinoids and beyond.” Nature Reviews Neuroscience (2014).
Miller, Lydia K., and Lakshmi A. Devi. “The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.” Pharmacological reviews 63.3 (2011): 461-470.
Monory, Krisztina, and Beat Lutz. “The endocannabinoid system as a therapeutic target in epilepsy.” Cannabinoids and the Brain. Springer US, 2008. 407-422.
Monteleone, Palmiero, et al. “Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa.” Neuropsychopharmacology 30.6 (2005): 1216-1221.
Pacher P, Steffens S (2009) The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 31: 63–77
Park, Jae Myung, et al. “Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study.” Journal of clinical gastroenterology 45.1 (2011): 45-49.
Pertwee, Roger G. “Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.” Philosophical Transactions of the Royal Society B: Biological Sciences 367.1607 (2012): 3353-3363.
Richardson, Jennelle Durnett, Lin Aanonsen, and Kenneth M. Hargreaves. “SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.” European journal of pharmacology 319.2 (1997): R3-R4.
Russo, Ethan B. “Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?" Neuroendocrinol Lett 25 2004 (1-2):31-39.
Russo, Ethan B. "Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes." Cannabis and Cannabinoid Research (2016b) 1:154-165.
Sam, Amir H., Victoria Salem, and Mohammad A. Ghatei. “Rimonabant: from RIO to ban.” Journal of obesity (2011).
Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, et al. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Frontiers in Bioscience (2011) 3: 308–314.
Siegling, Angela, et al. “Cannabinoid CB< sub> 1</sub> receptor upregulation in a rat model of chronic neuropathic pain.” European journal of pharmacology 415.1 (2001): R5-R7.
Siniscalco, Dario, et al. “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.” Journal of autism and developmental disorders 43.11 (2013): 2686-2695.
Sipe, Jack C., et al. “Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders.” Journal of leukocyte biology 78.1 (2005): 231-238.
Smith, Steele Clarke, and Mark S. Wagner. “Clinical endocannabinoid deficiency (CECD) revisited.” Neuroendocrinology Letters 35.3 (2014).
Ständer, Sonja, et al. “Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.” Journal of dermatological science 38.3 (2005): 177-188.
Storr, Martin A., et al. “Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.” Inflammatory bowel diseases 15.11 (2009): 1678-1685
Storr, M. A., et al. “The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.” Neurogastroenterology & Motility 20.8 (2008): 857-868.
Sugiura, Takayuki, et al. “2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain.” Biochemical and biophysical research communications 215.1 (1995): 89-97.
Volfe, Z., A. Dvilansky, and I. Nathan. “Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients.” International journal of clinical pharmacology research 5.4 (1984): 243-246.
Wallace, Melisa J., et al. “The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.” Journal of Pharmacology and Experimental Therapeutics 307.1 (2003): 129-137.
Wang L, Yang T, Qian W, Hou X (January 2011). “The role of endocannabinoids in visceral hyposensitivity induced by rapid eye movement sleep deprivation in rats: regional differences”. Int. J. Mol. Med. 27 (1): 119–26.